Therapy of metastatic malignant melanoma: on the way to individualized disease control.

Abstract excerpt

After decades of therapeutic frustration, the identification of some fundamental molecular drivers finally set the stage for the development of targeted therapies of metastatic malignant melanoma. With the invention of B-RAF inhibitors, targeting the mutated and activated B-RAF molecule in the MAP kinase cascade, objective responses can be achieved in about 50% of those cases harbouring this specific mutation....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antibodies
• Share to CTLA-4 Antigen
• Share to Melanoma, Cutaneous Malignant